loader from loading.io

Does the new Alzheimer's drug Aducanumab mean the end of Alzheimer's? with Marwan Sabbagh, MD.

Evolving Past Alzheimer's

Release Date: 06/30/2021

Strong Heart, Sharp Mind with Marwan Sabbagh MD show art Strong Heart, Sharp Mind with Marwan Sabbagh MD

Evolving Past Alzheimer's

A familiar guest rejoins us for the show! Marwan Sabbagh MD is currently a professor of Neurology at Barrow Neurological Institute and a leader in Alzheimer's disease diagnosis and treatment. Dr. Sabbagh and his bestselling co-author and heart disease survivor, Joe Piscatella reveals new hope for treating and preventing these heart, blood vessel, and brain diseases like Alzheimer's with their new book, Strong Heart, Sharp Mind. We discuss how, for the first time in his career, Dr Sabbagh is starting to see people with very early Alzheimer's hold the symptoms at bay. He attributes, in part, to...

info_outline
Plasma Exchange, Albumin & IVIg for Alzheimer's - AMBAR Trial Results with Merce Boada MD PhD show art Plasma Exchange, Albumin & IVIg for Alzheimer's - AMBAR Trial Results with Merce Boada MD PhD

Evolving Past Alzheimer's

The conversation had on this episode is a little complex but is an excellent review in how science is done and "how the sausage is made" in terms of medical evidence in peer review for Alzheimer's treatments.   We discuss the results of the - The Alzheimer Management by Albumin Replacement - where people with mild to moderate Alzheimer's showed significant improvements after having their blood plasma exchanged in addition to receiving either IV Albumin as well as IVIg (in some of the experimental groups).   The study doesn't offer an explanation of the mechanisms around why Albumin...

info_outline
Towards Understanding Towards Understanding "Lyme" & Alzheimer's Relationships with Alan MacDonald MD

Evolving Past Alzheimer's

In July 2021, the journal Frontiers in Neurology reported on "groundbreaking research" out of Tulane pointing to the relationship between Lyme disease and Alzheimer’s dementia.  But since the 1980s our guest on this episode, Dr. Alan MacDonald, was stirring up the scientific debate by publishing and presenting data from his pathology laboratory that the bacteria - Borrelia Burgdorferi  often synonymous with what's called Lyme disease, because of its association with its US origins in the town of Lyme, Connecticut. Dr. MacDonald graduated with an MD from Columbia University. ...

info_outline
Our Sense of Smell - Brainwaves of COVID and Alzheimer's with Thom Cleland PhD show art Our Sense of Smell - Brainwaves of COVID and Alzheimer's with Thom Cleland PhD

Evolving Past Alzheimer's

This is a more theoretical episode that gives us some idea about what might be happening with the rhythms of an Alzheimer's or POST-COVID brain.

info_outline
Our Brains Need Meditation - Here's Why  with Hemal Patel PhD  show art Our Brains Need Meditation - Here's Why with Hemal Patel PhD

Evolving Past Alzheimer's

In this episode, we go deep into the potential benefits of specialized meditation for our immune systems, brain-related proteins, Alzheimer's, cellular energy, and much more. Our guest, Dr Hemal Patel - is a full professor and serves as the Vice-Chair for Research in the Department of Anesthesiology at the University of California, San Diego.

info_outline
Lisa's Story - Chap. 2 - Living Well with Alzheimer's  show art Lisa's Story - Chap. 2 - Living Well with Alzheimer's

Evolving Past Alzheimer's

Earlier this year, podcast episode #65 - we spoke to Lisa and her daughters Stacy and Natalie. They told us about how they were Living Well with Alzheimer's and improving using lifestyle and personalized approach. Her cognitive decline had stabilized and seen small, but significant improvements in brain function.  This episode we review some of the elements  that have led to their success

info_outline
Usable Technology for Brain Aging & Dementia with Ben Hampstead PhD show art Usable Technology for Brain Aging & Dementia with Ben Hampstead PhD

Evolving Past Alzheimer's

“We’re actually able to change the brain, even in the face of things like Alzheimer’s disease.” This was the statement made by our guest for this show, Dr. Ben Hampstead. Dr. Hampstead is a professor at the Univ of Michigan and leads a lab that is doing several studies using transcranial direct current stimulation for mild cognitive impairment, Alzheimer's, and other forms of cognitive impairment. 

info_outline
Your Brain On Sugar  show art Your Brain On Sugar

Evolving Past Alzheimer's

Nikki Gould, a registered dietician at Kemper Cognitive Wellness is also joining us today to talk about what sugar can do to your brain and your overall health and how we can navigate the holidays with this information in mind.

info_outline
Working with Trauma in Alzheimer's & Dementia show art Working with Trauma in Alzheimer's & Dementia

Evolving Past Alzheimer's

Trauma can be defined as any event that alters how we process, react to, and recall memories, by overwhelming the individual’s central nervous system. Additionally, trauma is defined as any event in which a person feels helpless and unsafe. It is not only an occurrence that happened in the past; instead, trauma is an event that leaves an imprint upon the body and the brain which persists to the present day.

info_outline
Why I'm excited about Aducanumab (Aduhelm)! show art Why I'm excited about Aducanumab (Aduhelm)!

Evolving Past Alzheimer's

Dr. Nate Bergman quickly summarizes the story up the FDA's recent "accelerated approval" of Biogen's - Aducanumab (brand named, Aduhelm). He ends off with surprise about why he is excited about the approval...and it's probably not what you think! A quick, but useful listen.

info_outline
 
More Episodes

In this episode, we hear the argument in favor of the new Alzheimer's drug, Aducanumab (Aduhelm).  Dr. Marwan Sabbagh is a clinical and research leader at the Cleveland Clinic's Lou Ruvo Center for Brain Health. He was a doctor that saw patients in one of the trials that led to the FDA's Accelerated (provisional) Approval. 

Note: Dr. Sabbagh notes his disclosure as an advisor to Biogen, the maker of Aducanumab.

We discuss what Dr. Sabbagh noted in his own patients involved in the recent Phase 3 clinical trial of Aducanumab.

Controversy over the FDA's decision and why Dr. Sabbagh's 25+ years of diagnosing and treating Alzheimer's makes him optimistic about this drug.

Dr. Sabbagh talks through who he thinks might be a good candidate for Aducanumab, the drug's known practical side effects, and how people might get access to the medication in the near future.

Ultimately, Dr. Sabbagh sees people in the near future living with Alzheimer's like a chronic disease much like HIV or diabetes, or even cancer.

This episode presents a slightly different perspective than many of our listeners are used to.  We hope you find it useful.

 

2:33 - what is this new drug and how does it actually treat Alzheimer's 

5:28 - Why Dr. Sabbagh is optimistic about this new drug 

11:43 - Reasons for some of the skepticism around the study 

14:11 - Dr. Sabbagh’s observations of the people who have taken the drug 

21:10 - What are the risks of taking the drug? 

27:08 - Responding to the criticism of the drug 

32:30 - Other promising drugs that may be available in the future for Alzheimer's patients 

37:18 - How do people get access to this new drug?